1. Home
  2. GEG vs RNTX Comparison

GEG vs RNTX Comparison

Compare GEG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GEG

Great Elm Group Inc.

HOLD

Current Price

$2.17

Market Cap

69.7M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.92

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEG
RNTX
Founded
1994
2001
Country
United States
United States
Employees
50
10
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.7M
80.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GEG
RNTX
Price
$2.17
$0.92
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
18.3K
609.8K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.80
$0.85
52 Week High
$3.51
$2.18

Technical Indicators

Market Signals
Indicator
GEG
RNTX
Relative Strength Index (RSI) 52.25 45.01
Support Level $2.31 $0.85
Resistance Level $2.59 $1.33
Average True Range (ATR) 0.17 0.08
MACD -0.00 0.01
Stochastic Oscillator 28.68 54.47

Price Performance

Historical Comparison
GEG
RNTX

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: